GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » ROE %

Extrawell Pharmaceutical Holdings (HKSE:00858) ROE % : -40.95% (As of Sep. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Extrawell Pharmaceutical Holdings's annualized net income for the quarter that ended in Sep. 2023 was HK$-475.45 Mil. Extrawell Pharmaceutical Holdings's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was HK$1,161.12 Mil. Therefore, Extrawell Pharmaceutical Holdings's annualized ROE % for the quarter that ended in Sep. 2023 was -40.95%.

The historical rank and industry rank for Extrawell Pharmaceutical Holdings's ROE % or its related term are showing as below:

HKSE:00858' s ROE % Range Over the Past 10 Years
Min: -13.15   Med: 4.71   Max: 78.48
Current: -13.15

During the past 13 years, Extrawell Pharmaceutical Holdings's highest ROE % was 78.48%. The lowest was -13.15%. And the median was 4.71%.

HKSE:00858's ROE % is ranked worse than
74.6% of 996 companies
in the Drug Manufacturers industry
Industry Median: 4.225 vs HKSE:00858: -13.15

Extrawell Pharmaceutical Holdings ROE % Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings ROE % Chart

Extrawell Pharmaceutical Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.99 7.54 -11.15 11.89 10.56

Extrawell Pharmaceutical Holdings Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.49 7.35 7.75 13.46 -40.95

Competitive Comparison of Extrawell Pharmaceutical Holdings's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Extrawell Pharmaceutical Holdings's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Extrawell Pharmaceutical Holdings's ROE % falls into.



Extrawell Pharmaceutical Holdings ROE % Calculation

Extrawell Pharmaceutical Holdings's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Mar. 2022 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=129.265/( (1165.653+1281.722)/ 2 )
=129.265/1223.6875
=10.56 %

Extrawell Pharmaceutical Holdings's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Mar. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=-475.45/( (1281.722+1040.523)/ 2 )
=-475.45/1161.1225
=-40.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.


Extrawell Pharmaceutical Holdings  (HKSE:00858) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-475.45/1161.1225
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-475.45 / 60.282)*(60.282 / 1324.936)*(1324.936 / 1161.1225)
=Net Margin %*Asset Turnover*Equity Multiplier
=-788.71 %*0.0455*1.1411
=ROA %*Equity Multiplier
=-35.89 %*1.1411
=-40.95 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-475.45/1161.1225
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-475.45 / -471.59) * (-471.59 / -6.448) * (-6.448 / 60.282) * (60.282 / 1324.936) * (1324.936 / 1161.1225)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0082 * 73.1374 * -10.7 % * 0.0455 * 1.1411
=-40.95 %

Note: The net income data used here is two times the semi-annual (Sep. 2023) net income data. The Revenue data used here is two times the semi-annual (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Extrawell Pharmaceutical Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Extrawell Pharmaceutical Holdings (HKSE:00858) Business Description

Traded in Other Exchanges
N/A
Address
979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.
Executives
Mao Yumin 2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited 2201 Interest of corporation controlled by you
Ease Gold Investments Limited 2201 Interest of corporation controlled by you
Jnj Investments Ltd 2201 Interest of corporation controlled by you
United Gene Group Ltd 2201 Interest of corporation controlled by you
United Gene Holdings Limited 2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited 2101 Beneficial owner
Xie Yi 2201 Interest of corporation controlled by you
Huang Zhenping 2101 Beneficial owner
United Gene Industry Group Limited 2101 Beneficial owner
Chen Xuhua 2202 Interest of your spouse
Cheng Yong 2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings (HKSE:00858) Headlines

No Headlines